CONNECTING
HEALTHCARE
PROVIDERS
WITH PATIENTS TO
IMPROVE LIVES
OUR MISSION
Provepharm is driven to improve the lives of our patients, employees, and the ecosystem. We focus our resources on two main areas of development:
Main Areas of Development
Molecule Vitalization to fully optimize the molecule’s potential
Innovation of New Treatments for niche markets with unmet therapeutic or diagnostic need
PROVEPHARM IS AN INTERNATIONAL,
PRIVATE, PHARMACEUTICAL
COMPANY WITH A GLOBAL PRESENCE
IN OVER 30 COUNTRIES WORLDWIDE.
At Provepharm, we innovate in order to understand each molecule's full potential, to provide treatments that help patients. Provepharm is an international private company with a global presence in over 30 countries worldwide.
The company operates with integrity, as our goal is to have a positive, significant and sustainable impact on our planet’s ecosystem. As a responsible pharmaceutical company, we are committed to adhering to the US legislation and regulations that apply to our company's business. We act with honesty, transparency and sincerity in a spirit of mutual respect.
Efficiency is at the heart of our development model, notably by reducing time to market and broadening the accessibility of new treatments.
And, commitment is also demonstrated through the group’s social initiatives, the ultimate expression of our values and our sense of sharing.
The members of Provepharm are true trailblazers unafraid to venture into new areas in order to define new standards of innovation based on the development of the potential of existing molecules. We demonstrate the definition of cutting edge every day – as we strive to reinvent the model of pharmaceutical innovation and contribute to the improvement of the hospital practices and specialty care for the benefit of our customers and patients.
These values reflect our identity, our goals and embody our corporate culture. They characterize every Provepharm employee and are expressed through the daily actions of all our teams.
PRODUCTS
THAT MAKE A
DIFFERENCE IN
PEOPLE'S LIVES
At Provepharm, we innovate to unlock each molecule's full potential, to provide treatments that help improve patients' lives. Our portfolio of products meets the highest pharmaceutical quality standards, in the following areas: antidotes, diagnostics, injectable vitamins, metabolism, and neuroscience.
OUR HISTORY
Driven by an entrepreneurial spirit, privately-owned, Provepharm Life Solutions has more than two decades of continuous innovation and growth in the healthcare market. Here are a few highlights of the organization’s past, present, and future, where Provepharm will continue to develop healthcare solutions that improve patients’ lives.
Provence Technologies launched several internal research programs, including a process patented in 2006, by co-inventors Michel Feraud and Babak Sayah, for the manufacture of methylene blue, compliant with current international quality and regulatory requirements. A year later, Provepharm developed and commercialized healthcare products from these patented processes utilizing a highly pure, pharmaceutical - grade methylene blue.
Provepharm, acquires a company specialized in the chemical synthesis of peptides and proteins for therapeutic use. This is the first merger and acquisition operation opening a new development direction for the company in the field of biological pharmaceutical products.
Provepharm Life Solutions launches its new brand identity with the addition of multiple healthcare professionals joining the management team and executive board.
Provepharm Life Solutions acquires Apollo Pharmaceuticals USA, a company specializing in sterile injectable products, in the United States, as part of its diversification plan.
The early years: Michel Feraud, president, and founder, initially launched the company as “Provence Technologies”, a research and development chemistry laboratory, together with co-founder and friend Christophe Baralotto. The company operated as a contract research organization for international pharmaceutical, cosmetic, and agrochemical groups. Provence Technologies built its reputation by designing innovative molecule synthesis pathways and precise analytical methods, characterizing such products.
Provepharm obtained a centralized marketing authorization from EMA paving the way for the commercialization of injectable methylene blue with the brand name ProveBlue® in the 30 countries of the enlarged European Union.
Provepharm obtained FDA approval to commercialize
Provepharm Life Solutions joins forces with new strategic minority partners, Téthys Invest and ArchiMed.
Thanks to its solid financial structure, Provepharm Life Solutions continues to diligently develop and seek out unmet needs in the therapeutics and diagnostics area within the healthcare market to improve the quality of life for each patient it serves worldwide.